title: BRMS1 inhibits expression of NF-kappaB subunit p65, uPA and OPN in ovarian cancer cells.
abstract: BACKGROUND
  Breast cancer metastasis suppressor 1 (BRMS1) is a potent metastasis suppressor of various types of malignancies, including melanoma and ovarian cancer. Unfortunately, the clinical data regarding its role as a true metastatic suppressor and its efficacy as a prognostic marker and therapeutic target remain controversial. This study was designed to investigate the effect of BRMS1 on the invasion and metastasis of human ovarian cancer cells and its potential underlying mechanisms.
  
  
  METHODS
  BRMS1 small interfering RNAs (siRNAs) or control siRNAs were transfected into the OVCAR3 human ovarian cancer cell line. Invasion and migration activities were assessed using the Transwell invasion and migration assay. Protein levels of nuclear factor-kappaB (NF-kappaB) subunit p65, osteopontin (OPN) and urokinase-type plasminogen activator (uPA) were evaluated by Western blot, immunofluorescence and immunocytochemistry methods.
  
  
  RESULTS
  Successful knockdown of BRMS1 was verified by quantitative real-time RT-PCR and Western blot. The invasion and migration capacities of OVCAR3 cells were significantly enhanced in the BRMS1-silenced group, compared to controls (p < 0.05). Silencing of BRMS 1 significantly induced the expression of NF-kappaB subunit, p65, uPA, and OPN proteins.
  
  
  CONCLUSIONS
  BRMS1 inhibits expression of p65, uPA and OPN protein. In turn, this leads to inhibition of ovarian cancer cell invasion and metastasis. This study unveils a potential novel mechanism by which BRMS1 inhibits metastasis of ovarian cancer cells.
authors.forename: X J
authors.initials: XJ
authors.lastname: Sheng
authors.forename: D M
authors.initials: DM
authors.lastname: Zhou
authors.forename: Q
authors.initials: Q
authors.lastname: Liu
authors.forename: S Y
authors.initials: SY
authors.lastname: Lou
authors.forename: Q Y
authors.initials: QY
authors.lastname: Song
authors.forename: Y Q
authors.initials: YQ
authors.lastname: Zhou
mesh_terms: D045744:Cell Line, Tumor; D002465:Cell Movement; D005260:Female; D006801:Humans; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000235:genetics / Q000502:physiology*; D053495:Osteopontin / Q000037:antagonists & inhibitors* / Q000235:genetics; D010051:Ovarian Neoplasms / Q000473:pathology*; D034741:RNA, Small Interfering / Q000235:genetics; D012097:Repressor Proteins; D051996:Transcription Factor RelA / Q000037:antagonists & inhibitors* / Q000235:genetics; D014568:Urokinase-Type Plasminogen Activator / Q000037:antagonists & inhibitors* / Q000235:genetics
chemical_list: C410024:BRMS1 protein, human; D009363:Neoplasm Proteins; D034741:RNA, Small Interfering; D012097:Repressor Proteins; D051996:Transcription Factor RelA; D053495:Osteopontin; D014568:Urokinase-Type Plasminogen Activator